Barclays raised the firm’s price target on Privia Health (PRVA) to $24 from $23 and keeps an Equal Weight rating on the shares post the Q1 report. The company showed “steady progress” with modest outperformance in the fee-for-service business, well-controlled costs, and a clear path to 20% EBITDA growth in 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Group Approves Key Proposals at Meeting
- Privia Health’s Earnings Call Highlights Growth and Challenges
- Privia Health Group’s Strong Performance and Strategic Expansion Drive Positive Outlook
- Privia Health Reports Strong Q1 2025 Results
- Privia Health Group: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating